" class="no-js "lang="en-US"> Paul Stoffels - Medtech Alert
Saturday, June 15, 2024
Paul Stoffels

Paul Stoffels

About Paul Stoffels

Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.

Paul spearheads the Johnson & Johnson product pipeline by leading teams across all our sectors to set the company-wide innovation agenda, discovering and developing transformational healthcare solutions. He is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in resource-poor settings.

Paul’s vision for fueling the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry.

Previously, as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the R&D pipeline for Janssen Pharmaceutical Companies of Johnson & Johnson. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines.

Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined J&J in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition.

Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.

Related Story

Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older

November 25 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved […]

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA

October 21 2021

Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) […]

Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa

May 14 2021

Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and […]